ONWARD Medical N.V., a neurotechnology company developing spinal cord stimulation therapies to restore movement, function and independence in people with spinal cord injury (SCI) and other movement disabilities, has appointed Fouad Azzam as a non-executive member of its Board of Directors.
Azzam is a Partner at EQT Life Sciences, where he brings extensive experience in healthcare investments, corporate strategy and business development. Before joining EQT, he served as Managing Director of Eastman Ventures and held the position of Director at Eastman Chemical Company. During his tenure, he undertook several responsibilities across strategy, new business development and corporate development.
Earlier in his career, Azzam was part of the Research and Business Development group at Occidental Chemical Company, gaining experience in technology-driven business development and corporate growth.
He also brings significant board-level experience across the biotechnology and medical technology sectors. He currently serves on the boards of several companies, including Neuros Medical, Shinobi Therapeutics, HotSpot Therapeutics and Xycolor Therapeutics. His previous board appointments include medical technology companies Cardiac Dimensions, Endotronix and Simplify Medical.
Azzam holds a PhD in Chemical Engineering from the University of Akron and an MBA from the State University of New York at Buffalo.
His appointment adds considerable investment, strategic and corporate leadership experience to ONWARD Medical's Board of Directors. His background in life sciences and medical technology is expected to contribute valuable perspectives as the company advances its neurotechnology portfolio and works towards expanding treatment options for people living with spinal cord injuries and other movement disabilities.